You are here: Industry Insights > Ozempic

News List

Good News in the Chinese Diabetes Field and Several Original Research Drugs Underway PharmaSources/Dopine
May 25, 2021
Glad tidings came recently in terms of supervision of two domestic diabetes drugs. Semaglutide, Novo Nordisk's blockbuster hypoglycemic drug, advanced to the administrative approval stage (acceptance number: JXSS2000005/6) on April 20.
Lilly’s tirzepatide beats Ozempic in head-to-head type 2 diabetes trial pharmatimes
June 29, 2021
Eli Lilly has announced that its investigational GIP and GLP-1 inhibitor tirzepatide showed superiority over Novo Nordisk’s Ozempic in a Phase III trial.
Investigational 2 mg Dose of Ozempic (semaglutide) Injection Demonstrates Superior Reductions in Blood Sugar vs Ozempic 1 mg in Adults With Type 2 Diabetes in a Phase 3 Trial firstwordpharma
June 28, 2021
Novo Nordisk today presented data showing that an investigational 2 mg dose of Ozempic® (semaglutide) injection provided statistically significant and superior reductions in blood sugar (A1C) compared with Ozempic®1 mg.
FDA Approves New Indication for Ozempic, Updated Rybelsus Prescribing Information americanpharmaceuticalreview
January 19, 2020
Novo Nordisk announced the U.S. Food and Drug Administration (FDA) has approved a new indication for Ozempic® (semaglutide) injection 0.5 mg or 1 mg to reduce the risk of major adverse cardiovascular events (MACE) such as heart attack, stroke ...
Novo Nordisk secures FDA expanded indication for Ozempic pharmaceutical-technology
January 19, 2020
The US Food and Drug Administration (FDA) has approved a new indication for Novo Nordisk’s Ozempic (semaglutide). The once-weekly injection is now indicated to reduce the risk of major adverse cardiovascular events (MACE) ...
Novo's Ozempic launch kicks into gear ahead of oral semaglutide FDA decision fiercepharma
August 11, 2019
Novo Nordisk has suffered some well-documented insulin woes, but now the company has not just two, but three GLP-1 drugs stepping up to drive growth. And if all goes well at the FDA, another big approval is on tap this year.
Novo Nordisk files for EU approval of Ozempic in type II diabetes pharmatimes
April 28, 2019
Novo Nordisk has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Ozempic (oral semaglutide), for the treatment of type II diabetes.
Ozempic consistently reduced the risk of major cardiovascular events across type 2 diabetes populations at high CV risk regardless of prior CV events at baseline firstwordpharma
August 27, 2018
Munich, Germany, 26 August 2018 - Ozempic® (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack......
Novo Nordisk channels '70s 'Magic' in first TV ad for blockbuster-in-waiting Ozempic fiercepharma
August 02, 2018
Novo Nordisk debuted its first DTC campaign for Type 2 diabetes drug Ozempic this week, setting the promotional stage for its aspiring blockbuster.
Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver? fiercepharma
May 03, 2018
After Eli Lilly reported street-beating diabetes sales in the first quarter while Sanofi’s suffered, all eyes were turned to Novo Nordisk.

Previous page 1 2 Next page